Contribution: Industrial Research Assistance Program – Contributions to Firms
Arch Biopartners Inc.
$200,000.00
Pre-clinical and Clinical Development for LSALT Peptide to Treat Inflammation and Kidney Injury
FY 2018-19 · 2019-01-01
Summary
LSALT is a peptide drug and a selective non-enzymatic dipeptidase-1 antagonist and prevents leukocyte adhesion to endothelial cells creating numerous indications for targeting inflammation in the context of microbial and non-microbial (sterile) tissue injury. In pre-clinical mouse models, LSALT has proven efficacious in preventing acute kidney injury induced by ischemia-reperfusion, toxins and sepsis. LSALT patents have been assigned to Arch Biopartners Inc. who will manage drug development and human clinical trials for acute kidney injury as the first indication. Identification of new and more effective versions of LSALT is ongoing.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Toronto|Toronto, Ontario, Canada
Recipient Type
For-profit organization
Business Number
101328227
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2019-01-01 | 2018-19 | $200,000.00 |
| 1 | 2019-01-01 | 2018-19 | $200,000.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 182 days.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 182 jours.
Agreement End Date
2021-01-29
Agreement Number
919337
Agreement Start Date
2019-01-01
Agreement Title
Pre-clinical and Clinical Development for LSALT Peptide to Treat Inflammation and Kidney Injury
Agreement Title (French)
Développement préclinique et clinique du peptide LSALT pour le traitement de l'inflammation et des lésions rénales
Agreement Type
Contribution
Agreement Value
$200,000.00
Amendment Date
2020-10-29
Amendment Number
1
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
LSALT is a peptide drug and a selective non-enzymatic dipeptidase-1 antagonist and prevents leukocyte adhesion to endothelial cells creating numerous indications for targeting inflammation in the context of microbial and non-microbial (sterile) tissue injury. In pre-clinical mouse models, LSALT has proven efficacious in preventing acute kidney injury induced by ischemia-reperfusion, toxins and sepsis. LSALT patents have been assigned to Arch Biopartners Inc. who will manage drug development and human clinical trials for acute kidney injury as the first indication. Identification of new and more effective versions of LSALT is ongoing.
Description (French)
LSALT est un médicament peptidique et un antagoniste sélectif non enzymatique de la dipeptidase-1 et empêche l'adhésion des leucocytes aux cellules endothéliales, ce qui crée de nombreuses indications pour cibler l'inflammation dans le contexte de lésions tissulaires microbiennes et non microbiennes (stériles). Chez des modèles de souris précliniques, LSALT s'est révélé efficace pour prévenir les lésions rénales aiguës induites par l'ischémie-réperfusion, les toxines et la septicémie. Les brevets de LSALT ont été cédés à Arch Biopartners Inc., qui gérera le développement de médicaments et les essais cliniques chez l'humain pour les lésions rénales aiguës comme première indication. L'identification de nouvelles versions plus efficaces de LSALT est en cours.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Toronto--St. Paul's
Federal Riding (French)
Toronto--St. Paul's
Federal Riding Number
35090
NAICS Code
334512
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
101328227
Recipient City
Toronto|Toronto
Recipient Country
CA
Recipient Legal Name
Arch Biopartners Inc.
Recipient Postal Code
M4T 2M5
Recipient Province or Territory
ON
Recipient Type
F
Reference Number
172-2018-2019-Q4-919337
